Lyka Labs

Who are the top shareholders of the Lyka Labs?

The top shareholders of Lyka Labs primarily include promoters, with Ipca Laboratories Limited as the largest shareholder at 40.98%. Other notable shareholders are Thermo Capital Private Limited (1.55%) and individual investors (31.18%), along with minimal stakes from mutual funds and foreign institutional investors.

The top shareholders of Lyka Labs include several key players. The majority of the shares are held by promoters, with Ipca Laboratories Limited being the largest individual shareholder, holding 40.98%. Other notable shareholders include Thermo Capital Private Limited, which holds 1.55%, and individual investors collectively owning 31.18%. Additionally, there are four mutual fund schemes with a very small stake of 0.01% and five foreign institutional investors (FIIs) holding 0.23%. Overall, the promoter group plays a significant role in the ownership structure of Lyka Labs.

Who are in the management team of Lyka Labs?

As of March 2023, the management team of Lyka Labs includes Kunal Narendra Gandhi (Chairman & MD & CEO), Yogesh B Shah (Executive Director & CFO), and several independent and non-executive directors, overseeing the company's operations and strategy.

As of March 2023, the management team of Lyka Labs includes the following members:<BR><BR>1. Kunal Narendra Gandhi - Chairman & MD & CEO<BR>2. Sandeep P Parikh - Non-Executive & Independent Director<BR>3. Yogesh B Shah - Executive Director & CFO<BR>4. Dhara P. Shah - Non-Executive & Independent Director<BR>5. Kishore P Shah - Company Secretary & Compliance Officer<BR>6. Babulal Jain - Independent Director<BR>7. Prashant Godha - Director<BR>8. Shashil Mendonsa - Director<BR><BR>This team is responsible for overseeing the company's operations and strategic direction.

What does Lyka Labs do?

Lyka Labs Ltd is a micro-cap company in the Pharmaceuticals & Biotechnology sector, focusing on manufacturing formulations, bulk drugs, and healthcare products. As of March 2025, it reported net sales of 33 Cr and a net profit of 2 Cr, with a market cap of Rs 417 Cr.

Overview:<BR>Lyka Labs Ltd operates in the Pharmaceuticals & Biotechnology industry as a micro-cap company, focusing on manufacturing formulations, bulk drugs, and a range of healthcare products.<BR><BR>History:<BR>Lyka Labs Ltd was incorporated in April 1983, initially manufacturing formulations and later amalgamating with Lyphin Chemicals Pvt Ltd. The company has diversified over the years, including marketing medical and diagnostic equipment. The latest reported quarterly results show net sales and profit for March 2025.<BR><BR>Financial Snapshot:<BR>Net Sales: 33 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 2 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: Rs 417 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 50.00 <BR>Industry P/E: 35 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.37 <BR>Return on Equity: 7.99% <BR>Price to Book: 3.99 <BR><BR>Contact Details:<BR>Address: 4801/B & 4802/A, GIDC Industrial Estate Ankleshwar Gujarat : 393002 <BR>Tel: 91-02646-221422/220549 <BR>Email: companysecretary@lykalabs.com <BR>Website: http://www.lykalabs.com

Has Lyka Labs declared dividend?

No Dividend History Available

Who are the peers of the Lyka Labs?

Lyka Labs' peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Brooks Lab, Everest Organics, SMS Lifesciences, and Zenotech Lab. Lyka Labs has average growth and below average capital structure, with a 1-year return of 11.65%, higher than Cipla's but lower than Everest Organics' 252.60%.

Peers: The peers of Lyka Labs are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Brooks Lab., Everest Organics, SMS Lifesciences, and Zenotech Lab.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, and Lyka Labs, while Average management risk is found at Everest Organics, SMS Lifesciences, and Zenotech Lab. Growth is excellent at Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Average growth is noted at Lyka Labs, and Below Average growth is seen at Divi's Lab., Torrent Pharma, Brooks Lab., Everest Organics, SMS Lifesciences, and Zenotech Lab. Capital structure is excellent at Sun Pharma.Inds., Divi's Lab., Cipla, and Dr Reddy's Labs, while Below Average capital structure is noted at Lyka Labs, Brooks Lab., Everest Organics, and the rest.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Everest Organics at 252.60%, while the peer with the lowest is Cipla at 0.84%. Lyka Labs has a 1-year return of 11.65%, which is higher than Cipla's but lower than Everest Organics'. Additionally, peers with negative six-month returns include Lyka Labs and Zenotech Lab.

What is the technical trend for Lyka Labs?

As of June 2, 2025, Lyka Labs shows a mildly bearish trend, supported by daily moving averages and a bearish monthly MACD, despite mixed signals from the weekly MACD and Bollinger Bands.

As of 2 June 2025, the technical trend for Lyka Labs has changed from sideways to mildly bearish. The weekly MACD is mildly bullish, but the monthly MACD is mildly bearish, indicating mixed signals. The daily moving averages are also mildly bearish, reinforcing the bearish sentiment. Bollinger Bands on the monthly chart show a bearish trend, while both the KST and Dow Theory indicate no clear trend on a monthly basis. Overall, the current stance is mildly bearish, with the daily moving averages and monthly MACD being key indicators driving this outlook.

When is the next results date for Lyka Labs?

The next results date for Lyka Labs is August 1, 2025.

The next results date for Lyka Labs is scheduled for August 1, 2025.

How big is Lyka Labs?

As of 24th July, Lyka Labs Ltd has a market capitalization of 401.00 Cr and reported net sales of 138.50 Cr and a net profit of 8.27 Cr over the latest four quarters.

As of 24th July, <BR><BR>Market Cap: Lyka Labs Ltd has a market capitalization of 401.00 Cr, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 138.50 Cr, while the sum of Net Profit for the same period is 8.27 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period is March 2025, with Shareholder's Funds amounting to 103.55 Cr and Total Assets valued at 176.21 Cr.

How has been the historical performance of Lyka Labs?

Lyka Labs has shown fluctuating historical performance, with net sales increasing from 93.07 Cr in Mar'23 to 138.50 Cr in Mar'25, while total operating income peaked at 194.08 Cr in Mar'22 before declining. Despite rising costs and low cash flow, the company improved profitability, achieving a profit after tax of 7.93 Cr in Mar'25, recovering from previous losses.

Answer:<BR>The historical performance of Lyka Labs shows a fluctuating trajectory over the years, with notable improvements in recent periods.<BR><BR>Breakdown:<BR>Lyka Labs' net sales increased from 93.07 Cr in Mar'23 to 138.50 Cr in Mar'25, reflecting a positive growth trend. However, the total operating income peaked at 194.08 Cr in Mar'22 before declining to 138.50 Cr in Mar'25. The total expenditure, excluding depreciation, rose from 76.23 Cr in Mar'23 to 120.56 Cr in Mar'25, indicating rising costs. Operating profit (PBDIT) showed volatility, with a high of 103.24 Cr in Mar'22, dropping to 20.17 Cr in Mar'25. Profit before tax improved to 11.12 Cr in Mar'25 from a loss of 13.23 Cr in Mar'23, while profit after tax also turned positive at 7.93 Cr in Mar'25, recovering from losses in previous years. The company's total assets increased to 176.21 Cr in Mar'25, up from 151.52 Cr in Mar'23, and total liabilities also rose to 176.21 Cr in Mar'25. Cash flow from operating activities remained low at 1.00 Cr in Mar'25, with a net cash outflow of 4.00 Cr. Overall, while Lyka Labs has shown signs of recovery in profitability and sales, it continues to face challenges with rising costs and cash flow management.

Are Lyka Labs latest results good or bad?

Lyka Labs' latest results are concerning, showing a net loss of ₹3.36 crores for Q2 FY26, a 461.29% decline quarter-on-quarter and 260.00% year-on-year, alongside a negative operating margin of -6.93%. These figures indicate significant operational challenges and a negative outlook for the company's financial health.

Lyka Labs' latest results are concerning and can be classified as bad. The company reported a significant net loss of ₹3.36 crores for Q2 FY26, marking a dramatic decline of 461.29% quarter-on-quarter and 260.00% year-on-year. This loss is compounded by a negative operating profit of ₹2.54 crores, leading to an operating margin of -6.93%, a stark contrast to the positive margin of 11.17% in the previous quarter.<BR><BR>Net sales also fell by 10.93% year-on-year to ₹36.66 crores, despite a sequential increase of 10.99% from the previous quarter. This volatility in sales, combined with the catastrophic margin collapse, indicates severe operational challenges for the company.<BR><BR>Overall, these results reflect a fundamental breakdown in operational efficiency and cost management, raising significant concerns about the company's financial health and future prospects. Investors should be cautious, as the outlook appears negative without clear signs of recovery.

Is Lyka Labs overvalued or undervalued?

As of November 13, 2025, Lyka Labs is considered overvalued with a high PE ratio of 156.53 and a significant decline in performance, contrasting with its peers, which have more attractive valuations and growth expectations.

As of 13 November 2025, Lyka Labs has moved from an attractive to a fair valuation grade, indicating a shift in its perceived investment quality. The company is currently considered overvalued based on its high PE ratio of 156.53, an EV to EBIT of 119.79, and a Price to Book Value of 3.16. These ratios suggest that the stock is trading at a premium compared to its earnings and book value.<BR><BR>In comparison to its peers, Lyka Labs' PE ratio significantly exceeds that of Cipla, which stands at 22.65, and Dr. Reddy's Labs at 17.86, both of which are classified as attractive. Additionally, while Lyka Labs has a PEG ratio of 0.00, indicating no growth expectations, its peers like Sun Pharma and Divi's Lab are categorized as expensive with PEG ratios of 11.96 and 1.99, respectively. The recent performance of Lyka Labs shows a substantial decline, with a year-to-date return of -43.61%, contrasting sharply with the Sensex's positive return of 8.11% during the same period, further reinforcing the overvaluation narrative.

Should I buy, sell or hold Lyka Labs Ltd?

Which are the latest news on Lyka Labs?

Why is Lyka Labs Ltd falling/rising?

As of 08-Jan, Lyka Labs Ltd's stock price is at 79.00, down 1.64% over the last three days. Despite this short-term decline, the stock has shown positive returns over the past month and year-to-date, although it has significantly underperformed over the past year and three years.

As of 08-Jan, Lyka Labs Ltd's stock price is currently at 79.00, reflecting a decrease of 1.32, or 1.64%. The stock has been experiencing a downward trend, having fallen for the last three consecutive days, resulting in a total decline of 6.85% during this period. This recent performance is in contrast to its returns over the past week, where the stock has gained 2.37%, while the benchmark Sensex has declined by 1.18%.<BR><BR>Despite the recent drop, the stock has shown positive returns over longer periods, with a 6.17% increase over the past month and a year-to-date rise of 3.95%. However, it is important to note that the stock has significantly underperformed over the past year and three years, with declines of 49.68% and 38.88%, respectively, compared to the Sensex's gains.<BR><BR>The stock's trading activity indicates a rising investor participation, as evidenced by a delivery volume of 37.09k on January 7, which is up by 1.44% against the five-day average. This suggests that while the stock is currently falling, there is still interest from investors. Additionally, the stock is trading in a narrow range of Rs 0.24 and is above its 20-day moving averages, although it remains below the 5-day, 50-day, 100-day, and 200-day moving averages, indicating mixed signals in terms of momentum.<BR><BR>In summary, the recent decline in Lyka Labs Ltd's stock price can be attributed to a short-term downward trend despite some positive longer-term performance metrics and increasing investor participation.